Dose-Dense Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel With Trastuzumab and Lapatinib in HER2/neu–Overexpressed/Amplified Breast Cancer Is Not Feasible Because of Excessive Diarrhea

PURPOSE: Dose-dense doxorubicin and cyclophosphamide (AC) followed by paclitaxel and trastuzumab (PT) is feasible. Lapatinib is effective in the treatment of human epidermal growth factor receptor 2 (HER2) –positive metastatic breast cancer. We conducted a pilot study of dose-dense AC followed by PT...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Dang, Chau, Lin, Nancy, Moy, Beverly, Come, Steven, Sugarman, Steven, Morris, Patrick, Abbruzzi, Alyson, Chen, Carol, Steingart, Richard, Patil, Sujata, Norton, Larry, Winer, Eric, Hudis, Clifford
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2010
Matèries:
Original Reports
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3664034/
https://ncbi.nlm.nih.gov/pubmed/20479410
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.26.5900
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars